anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain a medicine useful for treating closed apnea, neutral apnea following sleep and their combined apnea, comprising an azapirone derivative compound as an active ingredient. CONSTITUTION: This therapeutic agent comprises a compound of formula I or formula II [Z is a group of formula III, formula IV, formula V, etc., (a dotted line and a solid line are each a single bond or a double bond; A is O, CH2 , CH=CH, etc.)] or its acid addition salt as an active ingredient. The agent can be prepared into a parenteral, oral or intrarectal administration form by a conventional method. A dose is 20-60mg per adult and administered in sleeping. Gepirone may be cited as the compound of formula I and MDL72832 as the compound of formula II. Anxiety, depression, fatigue, feebleness, excitation, anger, hostility, etc., as symptoms caused by sleep apnea can be relaxed.
A comparator cohort which includes new users of any dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonist, or other select antihyperglycemic agents (AHA) for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
TARPEYO (budesonide) delayed release capsules, for oral administration, contain budesonide, a synthetic corticosteroid, as the active ingredient. Budesonide is designated chemically as 16α, 17α-[(1RS)-Butylidenebis(oxy)]-11β, 21-dihydroxypregna-1,4-diene-3,20-dione. 

Budesonide is provided as a mixture of two epimers (22R and 22S). The empirical formula of budesonide is C25H34O6 and its molecular weight is 430.5. Its structural formula is: 

Budesonide is a white to off-white, tasteless, odorless powder that is practically insoluble in water, sparingly soluble in alcohol, and freely soluble in chloroform. 

The beads in each capsule contain the following inactive ingredients: sugar spheres (sucrose and starch), hypromellose, polyethylene glycol, citric acid monohydrate, ethyl cellulose, medium chain triglycerides and oleic acid. The capsule shells contain hypromellose and titanium oxide (E171); and the printing ink on the capsules contain shellac, propylene glycol and black iron oxide (E172). The enteric coating on the capsules contain: methacrylic acid and methacrylate copolymer, talc and dibutyl sebacate.
The treatment of the sham group was the same as active group. The only difference was that the coil was flipped 180° in the sham group. The device also made the same sound but could not stimulate the brain.
Patients having acute severe contusion spinal cord injury (cervical, thoracic or upper-lumbar) and ASIA A/B neurological deficit, within 7 days post-SCI, after primary decompressive and stabilizing surgery. All participants meet inclusion and exclusion criteria. All participants obtain 4 infusions of vehicle (sterile saline) with a 1-week interval. All participants are followed up for 12 months post-SCI.
PURPOSE: To obtain a liquid cosmetic composition capable of assuredly presenting cleansing effect after using tap water such as after bathing or face washing, essentially containing a residual free chlorine removing ingredient such as sodium thiosulfate and a cleansing ingredient such as crude drug powder. CONSTITUTION: This cosmetic composition essentially contains (A) ascorbic acid (salt), sodium thiosulfate, or a mixture thereof (pref. sodium thiosulfate) and (B) crude drug powder, crude drug extract, anti-inflammatory agent, cell activator, ultraviolet absorber, germicide, or a mixture thereof. The amount of the component A to be formulated is pref. 0.01-5wt.%, based on the whole composition, in the case of sodium thiosulfate, when the composition is to be directly sprayed or applied onto the skin. The amount of the component B to be formulated is pref. >=0.01wt.%, based on the whole composition, in terms of the original, crude drug, in the case of crude drug powder or extract, or >=0.001wt.% in the case of an anti-inflammatory agent such as allantoin, or cell activator such as vitamin E. It is preferable that the pH value of the composition be adjusted to 7-8.
OBJECTIVE: To investigate the association between body composition parameters and breast cancer (BC) risk in premenopausal women.
DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort study using data from the Kangbuk Samsung Cohort Study. Participants were women aged 20 to 54 years who were enrolled from 2011 to 2019 and followed up for BC development until December 31, 2020. Data were analyzed from June to August 2023.
EXPOSURES: Trained nurses conducted anthropometric measurements and assessed body composition using segmental bioelectric impedance analysis. The analysis encompassed adiposity measures such as body mass index (BMI), waist circumference, and body composition parameters, including muscle mass, fat mass, ratio of muscle mass to weight, ratio of fat mass to weight, and fat mass index.
MAIN OUTCOMES AND MEASURES: Adjusted hazard ratios (aHR) for BC during the follow-up period.
RESULTS: Among 125 188 premenopausal women, the mean (SD) age was 34.9 (6.3) years. During a mean (range) follow-up of 6.7 (0.5-9.9) years, 1110 incident BC cases were identified. The mean (SD) BMI and waist circumference were 21.6 (3.1) and 75.3 (8.2) cm, respectively. Higher BMI and waist circumference were associated with decreased risk, with an aHR of 0.89 (95% CI, 0.84-0.95) per SD increase in BMI and 0.92 (95% CI, 0.86-0.98) per SD increase in waist circumference. A higher ratio of fat mass to weight was associated with decreased BC risk (aHR, 0.92; 95% CI, 0.86-0.99 per SD increase), whereas the opposite trend was observed for the ratio of muscle mass to weight, with an aHR of 1.08 (95% CI, 1.02-1.15) per SD increase. The results remained consistent even after additional adjustments for height in the model. The fat mass index was also inversely associated with BC risk, with an HR of 0.90 (95% CI, 0.85-0.97) per SD increase.
CONCLUSIONS AND RELEVANCE: In this cohort study of premenopausal women, a higher level of adiposity, represented by increased BMI, waist circumference, and fat mass, was consistently associated with decreased breast cancer risk. Conversely, muscle mass and its ratio to weight displayed opposite or inconsistent patterns. These findings suggest an inverse association between excess adiposity and the risk of BC in premenopausal women, confirming earlier findings that BMI is an indirect measure of adiposity.
PURPOSE: A composition containing Broussonetia kazinoki Sieb water extract is provided to promote splenocyte and macrophage promotion. CONSTITUTION: A composition for enhancing immune functional contains Broussonetia kazinoki Sieb. extract as an active iigredient. A method for manufacturing the Broussonetia kazinoki Sieb. extract comprises: a step of collecting Broussonetia kazinoki Sieb. during manufacturing Korean paper, and a step of extracting Broussonetia kazinoki Sieb. stem using water at room temperature for 1 to 24 hours. The extraction is performed by hot water extraction, reflux extraction, ultrasonic wave extraction or stream extraction. A health food for enhancing immunity contains the composition as an active ingredient.
Necroptosis is a regulated necrotic cell death mechanism and plays a crucial role in the progression of cancers. However, the potential role and mechanism of necroptosis in colorectal cancer (CRC) has not been fully elucidated. In this study, we found that nuclear receptor subfamily 4 group A member 1 (NR4A1) was highly expressed in CRC cells treated with TNF-α, Smac mimetic, and z-VAD-FMK (TSZ). The depletion of NR4A1 significantly enhanced the sensitivity of CRC cells to TSZ-induced necroptosis, while NR4A1 overexpression suppressed these effects, as evidenced by the LDH assay, flow cytometry analysis of cell death, PI staining, and expression analysis of necrosome complexes (RIPK1, RIPK3, and MLKL). Moreover, NR4A1 deficiency made HT29 xenograft tumors sensitive to necroptotic cell death in vivo. Mechanistically, NR4A1 depletion promoted necroptosis activation in CRC through the RIG-I-like receptor pathway by interacting with DDX3. Importantly, the RIG-I pathway agonist poly(I:C) or inhibitor cFP abolished the effects of NR4A1 overexpression or suppression on necroptosis in CRC cells. Moreover, we observed that NR4A1 was highly expressed in CRC tissues and was associated with a poor prognosis. In conclusion, our results suggest that NR4A1 plays a critical role in modulating necroptosis in CRC cells and provide a new therapeutic target for CRC.
FIELD: medicine, diagnostics. SUBSTANCE: method is carried out in 0.05 M glycine-saline buffer solution at 8.2-8.25 pH by immobilization of globulin gamma immune to whooping cough agent, on the surface of polystyrene latex particles activated with methacrylic acid and zinc methacrylate. Immobilization is conducted in the presence of bovine serum albumin, polyethylene glycol and conservant. The latex applied is a mixture of polystyrene latex of 0.20-0.25 mcm and 1.1-1.2 mcm dispersibility. Components to obtain this preparation should be taken in certain weight ratios. EFFECT: higher efficiency and accuracy.
The first completed clinical trial of induced pluripotent stem cell (iPS cell)-derived cells was conducted in 15 participants with steroid-resistant acute graft-versus-host disease. After intravenous infusion of mesenchymal stromal cells (CYP-001 derived from a clone of human iPS cells), we reported the safety, tolerability and efficacy within the primary evaluation period at day 100. We now report results at the 2-year follow-up: 9 of 15 (60%) participants survived, which compares favorably with previously reported outcomes in studies of steroid-resistant acute graft-versus-host disease. Causes of death were complications commonly observed in recipients of allogeneic hematopoietic stem cell transplantation, and not considered by the investigators to be related to CYP-001 treatment. There were no serious adverse events, tumors or other safety concerns related to CYP-001. In conclusion, systemic delivery of iPS cell-derived cells was safe and well tolerated over 2 years of follow-up, with sustained outcomes up to 2 years after the first infusion. ClinicalTrials.gov registration: NCT02923375 .
The ANGEL-ASPECT is a multicentered, prospective, randomized, open-label, blinded end-point (PROBE) study. A total of approximately 488 patients (age from 18 to 80 years) within 24 hours of symptom onset of acute ischemic stroke, who has the imaging evidence of an occlusion of the Internal Carotid Artery (ICA) terminus and/or Middle Cerebral Artery Main Stem (MCA M1) segment, large infarct core \[ defined as: 1) NCCT (noncontrast computed tomography) ASPECTS (Alberta Stroke Program Early CT Score) 3-5, decided on last head CT scan before randomization. 2) Ischemic core volume ranges from 70-100ml, determined either on a diffusion-weighted MRI map based on an ADC (Apparent Diffusion Coefficient) threshold of less than 620 ×10-6mm2/s or on CTP (computed tomography perfusion) image with rCBF\<30%\] will be enrolled. Patients fulfilling all of the inclusion criteria and none of the exclusion criteria will be randomized 1:1 into two groups after offering informed content. One group will receive best medical management alone the other group will receive best medical management plus EVT including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty or stenting. The primary objective is to establish the efficacy of EVT in patients presenting with symptoms of acute ischemic stroke (AIS) from LVO in the anterior circulation and having a large infarct volume. The study consists of six visits including the day of randomization, 2 days after randomization, 7 days or discharge, and 30, 90 days and 1 year. Demographic information, symptoms and signs, laboratory test, neuro-imaging assessment neurological function rating scale will be recorded during the program. The primary endpoint is the modified Rankin's scale (mRS) at 90 days. The trial is anticipated to last from September 2020 to October 2022 with 488 subjects recruited form about 50 centers in China. All the related investigative organization and individuals will obey the Declaration of Helsinki and Chinese Good Clinical Practice standard. A Data and Safety Monitoring Board (DSMB) will regularly monitor safety during the study. The trial has been approved by Institutional Review Board (IRB) and Ethics Committee (EC) in Being Tiantan hospital, Capital Medical University.
To address this gap and to identify areas for better delivery of end-of-life services to patients with advanced CHF, the investigators propose to enrol a cohort of 300 patients with advanced CHF (New York Heart Association class III and IV), survey the participants every 4 months for a period of two years or till they die, whichever is earlier. The goal of this cohort study is to better understand the relationship between patient preferences, health care access, utilization, costs, and quality of life, and to identify strategies to improve the EOL experience for these patients. It is also important to recognize the significant role of the family in medical decision making in Asia. Previous studies from Singapore reveal that patients want their families to be involved in the decision making process. The role of the family in decision making is consistent with the Chinese culture of interdependency, obligations and filial piety. Decisions regarding treatment are often made by family caregivers, sometimes with little or no input from patients. Given this reality, the investigators will also enroll caregivers of the patients to evaluate their role in decision making for treatment of patients.
This is a retrospective multicentric study including advanced ovarian cancer patients that have used niraparib as first-line maintenance therapy after chemotherapy from fourteen hospitals in China between January 2019 and December 2021. The database lock-time was on December 31, 2022. All data were retrieved from the patients' medical records. Clinical data, including patient demographics, clinicopathological characteristics, residual disease after primary surgery, genetic-testing results and so on, were collected. Missing information was supplemented by telephone follow-up or face-to-face inquiries (only for patients who were alive and accessible). The incidence of AEs, as well as dose reductions, dose interruption, and discontinuation of treatment due to AEs were recorded.All analyses were performed on the safety population. The categorical variables were described as a frequency and percentage, and the continuous variables were described as a median and range. No formal sample size calculation was performed since the study was exploratory. Survival analyses were conducted using the Kaplan-Meier method and log-rank test. 95% confidence intervals (CIs) were calculated using the Clopper-Pearson method. Univariate and multivariate Cox regression models were established to determine factors that could affect the PFS for patients receiving niraparib maintenance treatment. Missing data were assigned as unknown for the univariate and multivariate analysis. The method of cox analysis was stepwise regression, and the screening criterion was Akaike Information Criterion (AIC). A P-value of \<0.05 was considered statistically significant. Descriptive statistics (number and percentage) were used to summarize the safety data by treatment. Statistical analyses were performed using the R software version 4.2.2 (R Project for Statistical Computing).
This study is aimed to examine and evaluate the true extent of the relationship between pressure pain threshold (PPT) and different aspects of somatic pain, by studying the interplay between PPT and different variables, and by further exploring the predictive capability of PPT values to estimate pain intensity, pain affect and disability associated with chronic low back pain (CLBP). In order to estimate these dimensions a calculator based on mathematical equations using different predictive models will be developed. This tool (calculator) will take into account PPT reading from the lower back region and some other variables having confounding effects on PPT and pain, and will be able to predict pain intensity, affect and associated disability with reasonable accuracy. Patients with chronic low back pain shall be the target population and shall be recruited through referrals from the medical Out-Patients Department of Institute of Physical Medicine \& Rehabilitation, Dow University of Health Sciences and Department of Rehabilitation Medicine PNS-Shifa Hospital, Karachi, Pakistan after initial screening in accordance with the inclusion and exclusion criteria. Screened patients shall then be briefed about the research project. After explaining the study objectives, procedures, potential benefits and discomforts, written informed consent shall be obtained from the patients. Only upon their agreement shall they become study participants and undergo assessments. The study participants shall receive handouts to document Depression and Anxiety, Pain Intensity, Pain Affect, and Disability. Pressure pain threshold (PPT) shall be measured using a manual Algometer. These measurements shall be followed by a session of physiotherapy treatment, after which Pain Intensity, Pain Affect, and Disability shall be recorded again.
<P>PROBLEM TO BE SOLVED: To provide a tranilast-containing preparation as a gel-like suspension preparation or micronized suspension useful as a scarring inhibitor or vitreous body visualizer after operation and having effects equivalent to or higher than the case with conventional continuous oral administration.  <P>SOLUTION: The gel-like suspension preparation contains tranilast or a pharmacologically acceptable salt thereof 1-4 μm in the center of particle size distribution and 5 μm or smaller in 90% median diameter and at least one of sodium hyaluronate and sodium chondroitin sulfate. This gel-like suspension preparation as an embrocation is useful as a scarring inhibitor after operation. The micronized suspension is obtained by mixing tranilast or a pharmacologically acceptable salt thereof and at least one of sodium hyaluronate and sodium chondroitin sulfate into a physiological saline solution followed by micronization, wherein the tranilast is 1-4 μm in the center of particle size distribution and 5 μm or smaller in 90% median diameter. This micronized suspension is useful as a vitreous body visualizer.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Approximately 500,000 women are diagnosed with cervical cancer annually, with high-grade cervical intraepithelial neoplasia (CIN) estimated to be 20 times higher. The diathermy ablation is an inexpensive minimally invasive surgeries for CIN. However, little is known about the treatment outcomes. A prospective clinical trial was therefore conducted to evaluate ablation outcomes based on detailed colposcopy findings, cytology, and biopsy results over a two-year period. We enrolled CIN2 (n = 32) and CIN3 (n = 7) patients. Eligibility criteria included: aged between 29 and 49 (median: 36, mean: 36.3), visible transformation zone with high-grade lesions not entirely occupying the cervix, and histologically diagnosed with CIN2 or CIN3. Cytology and HPV genotyping were performed, and colposcopic findings were evaluated. Colposcopy-guided diathermy ablation was conducted by a certified gynecologic oncologist. The incidence of recurrent or residual disease was 5.1% (2/39, 95% confidence interval: - 0.02 to 0.12). The prevalence of HPV infection at 12 months decreased after surgery, as 67.6% (23/34, 0.52-0.83) of patients were HPV-negative. No severe adverse events were reported, while there were five pregnancies with full-term deliveries. The promising outcome was possibly due to selection of rigorous surgical indication and skilled surgical techniques. The study highlights the importance of experienced and skilled colposcopists.TrialRegistry This study was registered in the clinical trial registration system of the University hospital Medical Information Network Clinical Trials Registry (UMIN-CTR ID: UMIN000024483). Open for the trial to the public through the website: 01/11/2016. First registration of the patient: 30/01/2017.
Crystalline or amorphous zinc insulin having a zinc content of 2.72 to 8.00 per cent by weight is prepared by reacting a suspension or solution of crystalline or amorphous insulin with a zinc compound in a liquid medium which does not take part in the reaction, which is a weak organic base, e.g. amines, amides, pyridines, a cresol, a phenol, an organic acid, a monovalent or polyvalent alcohol or a compound or derivative thereof, e.g. esters, ethers, ketones and halogen- or thio-derivatives of said substances, and which contains between 0 and 85 per cent by weight of water.  The liquid medium may contain substances which prevent the precipitation of zinc hydroxide, e.g. ammonium chloride in ammonia solution, potassium or ammonium salts of ethylenediamine tetracetic acid, tri(acetic acid) amine, and aminoacetic acid. Specific liquid media disclosed are glacial acetic, lactic, glycollic, formic, and propionic acids, ethyl alcohol, anhydrous phenol, benzyl alcohol, glycol, glycerol, thiodiglycol, 3-chloro-1 : 2 - propanediol, 1 - phenol - 4 - sulphonic acid, methyl acetate, chloroacetic ethyl ester, acetone, aniline and pyridine. Specified zinc compounds are zinc chloride, sulphate or acetate or if the medium is acidic, zinc oxide or hydroxide.  Injectable suspensions of zinc insulin may be prepared in water or resorbable organic liquids, e.g. vegetable or animal oils such as peanut oil, which may also contain sodium chloride and acetate, phenol and tricresol, and ions of at least one of the metals zinc, calcium or magnesium may also be added.
Subjects receive 180 mg of ticagrelor immediately after study enrollment. OCT is performed prior to and after coronary artery stenting.
Sorafenib two times a day every day for 28 days. Beginning on Day 15 (Week 2), rapamycin will be taken every day until the end of the cycle (Day 28). After Day 28, rapamycin and sorafenib can continue to be taken daily until the cancer gets worse or serious side effects are experienced.